Intact presupplementary motor area function in early, untreated Parkinson's disease

Movement Disorders

Volumn 23, Issue 12, 2008, Pages 1756-1759

  Martin, W R Wayne ^a,b   Wieler, Marguerite ^a   Gee, Myrlene ^a   Hanstock, Christopher C ^a   Camicioli, Richard M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b GLENROSE REHABILITATION HOSPITAL   (Canada)

Author keywords

Magnetic resonance spectroscopy; Parkinson's disease; Supplementary motor area

Indexed keywords

CHOLINE; CREATINE; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; MALE; MOTOR CORTEX; MOTOR DYSFUNCTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PRESUPPLEMENTARY MOTOR CORTEX; PRIORITY JOURNAL;

AGED; ASPARTIC ACID; CASE-CONTROL STUDIES; CHOLINE; CREATINE; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MOTOR CORTEX; PARKINSON DISEASE;

EID: 57049085157     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22101     Document Type: Article

References (17)

1. Fukuda M, Mentis M, Ma Y, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. Brain 2001; 124:1601-1609.
2. Sabatini U, Boulanouar K, Martin F, et al. Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain 2000;123:394-403.
3. Thobois S, Dominey P, Decety J, et al. Motor imagery in normal subjects and in asymmetrical Parkinson's disease: a PET study. Neurology 2000;55:996-1002.
4. Cunnington R, Egan G, O'Sullivan J, Hughes A, Bradshaw J, Colebatch J. Motor imagery in Parkinson's disease: a PET study. Mov Disord 2001;16:849-857.
5. Macdonald V, Halliday GM. Selective loss of pyramidal neurons in the presupplementary motor cortex in Parkinson's disease. Mov Disord 2002;17:1166-1173.
6. Camicioli RM, Hanstock CC, Bouchard TP, Gee M, Fisher NJ, Martin WRW. Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease. Mov Disorders 2007;22:382-386.
7. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32(Suppl):S125-S127.
8. Fahn S, Elton RL. Uni.ed Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease, Vol. 2. Florham Park, NJ: Macmillan Healthcare; 1987. p 153-163.
9. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30:672-679.
10. Lucetti C, Del Dott P, Gambaccini G, et al. Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study. Mov Disord 2007;22:2170-2175.
11. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm 2000;107:1027-1063.
12. 1HMR spectroscopy in common dementias. Neurology 2004;63:1393-1398.
13. Picard N, Strick PL. Imaging the premotor areas. Curr Opin Neurobiol 2001;11:663-672.
14. Colebatch JG. Bereitschaftspotential and movement-related potentials: origin, significance, and application in disorders of human movement. Mov Disord 2007;22:601-610.
15. Boecker H, Dagher A, Ceballos-Baumann AO, et al. Role of the human rostral supplementary motor area and the basal ganglia in motor sequence control: investigations with H215O PET. J Neurophysiol 1998;79:1070-1080.
16. Haslinger B, Erhard P, Kampfe N, et al. Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain 2001;124:558-570.
17. Buhmann C, Glauche V, Stürenburg HJ, Oechsner M, Weiller C, Büchel C. Pharmacologically modulated fMRI-cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients. Brain 2003; 126:451-461.